Syngene International has lowered its FY27 revenue outlook following a 16% year-on-year drop in June quarter revenue. The company is dealing with reduced orders from its largest client, Zoetis, and concerns over high leadership turnover.
Syngene International is facing a challenging operational phase as it works to address a decline in business momentum. Executive Chairperson Kiran Mazumdar-Shaw recently acknowledged that the company became too dependent on its largest client, Zoetis, which led to a significant impact on performance when that client reduced its orders. The reduction in demand for biologics, specifically linked to the canine drug Librela, has forced the company to reassess its growth trajectory.
Financial Impact and Margin Pressure
In the June 2026 quarter, the company reported a 16% year-on-year decline in revenue, which stood at ₹736 crore. Profitability has also felt the impact, with EBITDA margins narrowing to 12%. This drop is largely attributed to the lower manufacturing volumes supplied to Zoetis. As a result, Syngene has adjusted its financial outlook for FY27, now expecting a mid-single-digit decline in revenue. This marks the third straight year that the company has had to revise its guidance, creating uncertainty for investors regarding the timeline for a recovery.
Strategic Challenges and Leadership Changes
Beyond the issues with its main client, the company is managing a transition away from commoditized research services, which have faced intense pricing pressure from lower-cost competitors. With nearly 78% of revenue coming from its discovery services segment, the company is working to pivot back toward higher-value offerings, such as AI-enabled drug discovery, to improve its competitive standing. Furthermore, the company has seen significant churn in its senior leadership over the past three years. This instability has complicated the execution of its business strategy, raising concerns among market observers about the company's internal stability during this transition period.
Comparison with Peers
Syngene’s recent performance has been contrasted with other players in the contract research and manufacturing space, such as Divi's Laboratories, Laurus Labs, and Sai Life Sciences. While these peers have generally shown more consistent growth metrics and operational execution, Syngene is currently working through a rebuilding phase. The company's stock has faced significant selling pressure over the past year, reflecting these challenges in earnings and the need for a diversified client base.
Management has labeled FY27 as a year for rebuilding, with a primary focus on increasing the utilization of its manufacturing facilities and diversifying its customer portfolio. Investors will likely be tracking the company’s ability to secure new contracts and restore its profit margins in the coming quarters. The effectiveness of the new commercial organization and the ability to stabilize leadership roles will be key areas to watch as the company attempts to return to a path of sustainable growth by FY28.